RLAY (Relay Pharma) Long-Term Debt

Corporate emblem and logo of Relay Corp (RLAY)

The price action of Relay Therapeutics (RLAY) is driven by the implementation of IT methods in US laboratories, where financial stability is paired with unique protein analysis. The current indicator is 0.03. The business relies on the Dynamo platform and a partnership with Pfizer to develop precision medicines, while the automation of cleanroom upgrades eliminates downtime across research and production complexes.

RLAY (Relay Pharma) Company Long-Term Debt history from 07/04/2022 to 10/28/2026

Financial and market metric breakdowns for Relay Pharma (RLAY)

- price and consensus price forecast:
Stock Quotes relaytx.com|RLAY - Price Target Chart
- market capitalization data:
Market Value Relay Therapeutics|RLAY - Total Company Value
- book capitalization data:
Net Assets per Single Share Relay Therapeutics|RLAY - Company Book Value|Market-to-Book Ratio relaytx.com|RLAY - Company Total Assets
- debt and liquidity data:
Debt to Capital Ratio Relay Therapeutics|RLAY - Long-Term Debt to Equity Ratio|Current Liabilities to Capital Relay Corp|RLAY - Company Total Debt|Debt to Net Assets Ratio Relay Therapeutics|RLAY - Company Long-Term Liabilities|Amount of Current Liabilities Relay Therapeutics
Comprehensive company analysis:RLAY - relaytx.com
Mass-produced product of Relay Therapeutics, Inc.

Assessing the investment reliability of equity assets requires an analysis of the liability structure, where long-term debts measure the total volume of borrowed capital with a maturity exceeding one year. For Relay Therapeutics (RLAY), this parameter reflects the cost of the digital transformation of drug development, which is confirmed by monitoring the organization's long-term financial debt as a balance between ESG innovations and debt load.

Competitors of Relay Therapeutics

genmab.com - Company Long-Term Liabilities|EXEL (Exelixis) - Company Long-Term Debt|NUVL: Long-Term Debt|Kymera Therapeutics Inc (KYMR) - Company Long-Term Debt|IDYA (IDEAYA Corp) - Company Long-Term Debt|Company Long-Term Debt ELVN (Enliven Therapeutics)|Long-Term Debt oricpharma.com|NRIX: Company Long-Term Debts|Long-Term Indebtedness Tyra Biosciences Inc TYRA|VSTM: Company Long-Term Liabilities|GLUE - Long-Term Debt|Company Long-Term Liabilities Cullinan Therapeutics (CGEM)|immuneering.com (IMRX) - Company Long-Term Loans and Borrowings|CCCC - Company Long-Term Liabilities|Black Diamond Therapeutics, Inc. (BDTX) - Amount of Long-Term Liabilities|RPTX (Repare Rx) - Company Long-Term Debts|Company Long-Term Debts PMVP|Karyopharm Therapeutics (KPTI) - Company Long-Term Debt|Company Long-Term Loans and Borrowings propanc.com (PPCB)|BGMS (Bio Green Med Solution) - Company Long-Term Debts|Long-Term Indebtedness Aadi Bioscience Inc AADI|ALRN (Aileron) - Company Long-Term Debts|Blueprint Medicines (BPMC) - Long-Term Debt|GLYC - Company Long-Term Liabilities|springworkstx.com (SWTX) - Amount of Long-Term Liabilities